PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London open: Stocks at one-month high as Vodafone, RBS gain

Fri, 21st Feb 2014 08:47

- Vodafone, RBS and Glaxo provide a lift- IHG, Glencore Xstrata hit by downgrades- FTSE 100 at highest intraday level in monthtechMARK 2,891.98 +0.55%FTSE 100 6,840.31 +0.40%FTSE 250 16,419.58 +0.31% Strong gains from heavyweights Vodafone, RBS and GlaxoSmithKline gave UK markets a boost on Friday with stocks rising to levels not seen in a month.The FTSE 100 was trading 0.4% higher at 6,840 early on, its highest intraday level since January 22nd.A decent performance on Wall Street last night has helped to spur buying this morning, as US indices turned around after a poor start as data showed that manufacturing activity Stateside rose to a four-year high."I think this clearly highlights the fact that the market is still generally bullish and is once again looking for any excuse to buy," said Market Analyst Craig Erlam from Alpari.After a data-heavy week, today's session is set to be a little quieter on the macro front, though UK retail sales and public-sector borrowing figures will catch investors' attentions this morning.Vodafone, RBS and Glaxo provide a liftTelecoms titan Vodafone was making decent gains this morning with shareholders set to receive a windfall from the company's sale of its 45% stake in Verizon Wireless. The $130bn cash and shares deal is set to complete today.RBS was higher amid reports that the bank will announce plans to slash as many as 30,000 jobs, reducing its staff count to the lowest levels in more than 10 years.Pharmaceuticals giant GlaxoSmithKline was higher after European regulators recommended marketing authorisation for umeclidinium, its once-daily treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.Millennium & Copthorne, the FTSE 250 hotel firm, jumped after reporting record revenues and profits for 2013 as fourth-quarter results were boosted by the one-off sale of the bulk of the Glyndebourne development in Singapore.Sector peer InterContinental Hotels Group, however, was trading in the red after Credit Suisse lowered its recommendation to 'underperform', pointing out that the shares are trading within just 4% of their all-time high at a price-to-earnings ratio of 23.Glencore Xstrata was also lower after JPMorgan Cazenove downgraded its rating on the stock to 'neutral', saying that its peers have overtaken it in terms of capital returns potential.FTSE 100 - RisersVodafone Group (VOD) 236.00p +2.79%Royal Bank of Scotland Group (RBS) 361.70p +1.69%ARM Holdings (ARM) 962.50p +1.64%Persimmon (PSN) 1,459.00p +1.53%Prudential (PRU) 1,370.00p +1.11%Barclays (BARC) 258.05p +1.10%Aviva (AV.) 473.40p +1.09%BAE Systems (BA.) 404.70p +1.07%British Land Co (BLND) 702.50p +0.93%Compass Group (CPG) 925.50p +0.93%FTSE 100 - FallersGlencore Xstrata (GLEN) 333.05p -2.17%InterContinental Hotels Group (IHG) 1,934.00p -2.08%Smiths Group (SMIN) 1,366.00p -1.73%IMI (IMI) 1,544.00p -1.34%Mondi (MNDI) 1,032.00p -1.24%Anglo American (AAL) 1,536.50p -1.13%Morrison (Wm) Supermarkets (MRW) 239.50p -1.07%Fresnillo (FRES) 975.00p -1.02%easyJet (EZJ) 1,732.00p -0.92%Antofagasta (ANTO) 942.50p -0.84%FTSE 250 - RisersMillennium & Copthorne Hotels (MLC) 598.00p +4.64%Essentra (ESNT) 875.00p +3.55%IP Group (IPO) 221.00p +3.22%Petra Diamonds Ltd.(DI) (PDL) 170.10p +3.03%Centamin (DI) (CEY) 51.70p +2.48%Morgan Advanced Materials (MGAM) 341.40p +1.88%Laird (LRD) 328.30p +1.77%Informa (INF) 531.00p +1.72%Afren (AFR) 156.10p +1.63%AL Noor Hospitals Group (ANH) 917.50p +1.61%FTSE 250 - FallersVesuvius (VSVS) 462.70p -1.91%Telecity Group (TCY) 669.50p -1.69%Electra Private Equity (ELTA) 2,439.00p -1.45%Dechra Pharmaceuticals (DPH) 675.50p -1.39%Xaar (XAR) 1,095.00p -1.35%Evraz (EVR) 82.10p -1.20%Crest Nicholson Holdings (CRST) 375.00p -1.19%Debenhams (DEB) 74.25p -0.93%UK Commercial Property Trust (UKCM) 78.00p -0.83%Domino's Pizza Group (DOM) 543.50p -0.82%BC
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.